High dose chemoradiotherapy and Asct may overcome the prognostic importance of biologic markers in relapsed/refractory hodgkin lymphoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 18, Issue 1, 2010, Pages 35-40

  Persky, Daniel O ^a   Moskowitz, Craig H ^a   Filatov, Alexander ^b   Saxena, Rakhee ^b   Cui, Haiyan ^c   Teruya Feldstein, Julie ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Biometry ^*  (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Autologous stem cell transplant (ASCT); Biomarkers; Chemoradiotherapy; Relapsed refractory Hodgkin lymphoma

Indexed keywords

BIM PROTEIN; BIOLOGICAL MARKER; CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; INTERLEUKIN 6; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; CARBOPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; IFOSFAMIDE; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 76149111943     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181b473b7     Document Type: Article

References (23)

1. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002; 359:2065-2071.
2. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97: 616-623.
3. Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol. 2004;124:645-652.
4. Amini RM, Enblad G, Engstrom P, et al. Relapsed Hodgkin's lymphoma: immunostaining patterns in relation to survival. Leuk Lymphoma. 2002;43:1253-1260.
5. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed- Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101:681-689.
6. Montalban C, Garcia JF, Abraira V, et al. Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol. 2004;22: 1664-1673.
7. Sup SJ, Alemany CA, Pohlman B, et al. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol. 2005;23:3773-3779.
8. O'Brien PC. A nonparametric test for association with censored data. Biometrics. 1978;34:243-250.
9. Smolewski P, Robak T, Krykowski E, et al. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6:1150-1160.
10. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002;100:3935-3941.
11. Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood. 1997;90:2429-2436.
12. Xerri L, Bouabdallah R, Camerlo J, et al. Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol. 1994;25:449-454.
13. Brink AA, Oudejans JJ, van den Brule AJ, et al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Mod Pathol. 1998;11:376-383.
14. Vassallo J, Metze K, Traina F, et al. The prognostic relevance of apoptosis-related proteins in classical Hodgkin's lymphomas. Leuk Lymphoma. 2003;44:483-488.
15. Spector N, Milito CB, Biasoli I, et al. The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma. Leuk Lymphoma. 2005;46:1301-1306.
16. Rassidakis GZ, Medeiros LJ, McDonnell TJ, et al. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res. 2002;8:488-493.
17. Deng J, Carlson N, Takeyama K, et al. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12:171-185.
18. Bai M, Papoudou-Bai A, Horianopoulos N, et al. Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas. Hum Pathol. 2007;38:103-113.
19. Reynolds GM, Billingham LJ, Gray LJ, et al. Interleukin 6 expression by Hodgkin/Reed-Sternberg cells is associated with the presence of "B" symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br J Haematol. 2002;118:195-201.
20. Casasnovas RO, Mounier N, Brice P, et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2007;25: 1732-1740.
21. Gorschluter M, Bohlen H, Hasenclever D, et al. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol. 1995;6:477-482.
22. Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res. 1993;53:2118-2122.
23. Seymour JF, Talpaz M, Hagemeister FB, et al. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med. 1997;102:21-28.